Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically
develops on the background of chronic liver disease and is an aggressive disease with …

The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …

Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell …

MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs).
These alterations are associated with increased MET activity and preclinical sensitivity to …

PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
demonstrated superior progression-free survival (PFS) and improved health-related quality …

Brain, the major organ of the central nervous system controls and processes most of body
activities. Therefore, the most aggressive brain tumor–glioblastoma and metastases from …

The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and
progression-free survival, and a higher proportion of patients with a confirmed complete or …

Currently, there is a huge demand to develop chemoimmunotherapy with reduced systemic
toxicity and potent efficacy to combat late-stage cancers with spreading metastases. Here …